Incretin-based therapies, such as GLP-1s and GIPs, have transformed treatment for people with Type II Diabetes (T2D) and obesity. In turn, many clinicians have harnessed these medications to help patients achieve greater weight loss and improved glycemic control. As GLP-1/GIP use continues to rise, UI Health Care Endocrinologist Kathleen Robinson, MD, PhD, wanted to examine whether medical […]